Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04716231 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atacicept in Subjects With IgA Nephropathy

Study acronym: ORIGIN 3
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Vera Therapeutics, Inc.

Record History

  1. Primary endpoint(s) modified Results posted: Oct 1, 2026 · Final enrollment: 428 participants (planned 376) · Eligibility criteria expanded, about 11 words · 2 more Show 5 more changesShow less
    • Results posted: Oct 1, 2026
    • Final enrollment: 428 participants (planned 376)
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints shortened, about 10 words
    • Publications: details revised at 3 of 3 entries
  2. Start date: May 23, 2023 to Jun 29, 2023v26
  3. Primary completion date changed from estimate of May 2025 to May 15, 2025v25
  4. Study description shortened, about 8 wordsv24 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv23 Show 1 more changeShow less
    • Site details revised
Show 21 earlier versionsHide 21 earlier versions
  1. Study Identification, Study Status, Oversight, Contacts/Locationsv22
  2. Primary completion date: Jun 2025 to May 2025v21
  3. Re-verified, no change to tracked fieldsv20
  4. Secondary endpoint revisedv19 See this version in full on ClinicalTrials.gov ↗
  5. Study site revisedv18 See this version in full on ClinicalTrials.gov ↗
  6. Phase: Phase 2/3 to Phase 3 Primary endpoints: 2 to 1 · Enrollment target: 492 to 376 · Study sites: 82 to 1 · 4 morev17 Show 7 more changesShow less
    • Primary endpoints: 2 to 1
    • Enrollment target: 492 to 376
    • Study sites: 82 to 1
    • Eligibility criteria shortened, about 35 words
    • Secondary endpoints: 2 to 1
    • Study description shortened, about 38 words
    • Study arms: 6 to 2

    See this version in full on ClinicalTrials.gov ↗

  7. Phase: Phase 2 to Phase 2/3 Trial status: Active, Not Recruiting to Recruiting · Enrollment target: 116 to 492 · Primary completion date: Mar 2023 to Jun 2025 · 8 morev16 Show 11 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 116 to 492
    • Primary completion date: Mar 2023 to Jun 2025
    • Start date: May 18, 2021 to May 23, 2023
    • Primary endpoints: 1 to 2
    • Study sites: 76 to 82
    • Completion date: Jul 2024 to Jul 2028
    • Eligibility criteria expanded, about 54 words
    • Secondary endpoints: 1 to 2
    • Study description expanded, about 112 words
    • Study arms: 4 to 6

    See this version in full on ClinicalTrials.gov ↗

  8. Primary completion date: Dec 2022 to Mar 2023v15
  9. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 105 to confirmed 116 · Site details revised at 76 of 76 sitesv14 Show 2 more changesShow less
    • Enrollment target: estimated 105 to confirmed 116
    • Site details revised at 76 of 76 sites
  10. Study sites: 75 to 76v13
  11. Study sites: 64 to 75v12
  12. Study sites: 60 to 64v11
  13. Study sites: 57 to 60v10
  14. Study sites: 54 to 57v9
  15. Study sites: 48 to 54v8
  16. Study sites: 47 to 48v7
  17. Study sites: 35 to 47 Eligibility criteria shortened, about 8 wordsv6 Show 1 more changeShow less
    • Eligibility criteria shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  18. Study sites: 23 to 35v5
  19. Study sites: 6 to 23v4
  20. Study sites: 3 to 6v3
  21. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Study sites: 0 to 3 · Start date changed from estimate of Apr 2021 to May 18, 2021 · 3 morev2 Show 6 more changesShow less
    • Primary endpoint revised
    • Study sites: 0 to 3
    • Start date changed from estimate of Apr 2021 to May 18, 2021
    • Eligibility criteria revised
    • Secondary endpoint revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Trial Details
NCT Number NCT04716231
Lead Sponsor Vera Therapeutics, Inc.
Conditions IgA Nephropathy, Berger Disease
Enrollment 428 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov